ClinicalTrials.gg
Status unknownNCT05602480Updated Nov 17, 2022

Phase I Clinical Trial of a Candidate PCV13 in Healthy People

A Phase 1 interventional study of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine and 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine in Pneumococcal Infections, sponsored by Wuhan BravoVax Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 6 Weeks and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-17.

Sponsored by Wuhan BravoVax Co., Ltd. · Phase 1, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Nov 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
264
Allocation
Randomized
Ages
6 Weeks and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.

Planned enrollment
26th of 44
264 · median 328
Started
2022
with 2 others
Phase 1
6 of 44
none open now
Registered
42nd of 44
by date

Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 26th largest by planned enrollment, is one of 3 that started in 2022, is one of 6 in phase 1, and was the 42nd registered.

Pneumococcal Infections

298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →

About 13-valent pneumococcal vaccine

13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 6 Weeks and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections as a file.
02

Study summary

Streptococcus pneumoniae is a major cause of morbidity and mortality in children worldwide, resulting in up to 1 million pediatric deaths every year. Since the licensure of PCV7, PCV10, PCV13 and PCV15, the reported overall decline in invasive pneumococcal disease in hospitalized children younger than 5 years is approximately 60% around the world.

This is a single center, blinded, randomized, positive-controlled phase I clinical trial to evaluate the safety and explore the immunogenicity of a candidate PCV13 in healthy people aged 2 months (minimum 6 weeks) and above.

03

Conditions studied

  • Pneumococcal Infections

Keywords

  • Pneumonia, Pneumococcal
04

Who can participate

Ages eligible
6 Weeks and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Satisfy the age requirements of the clinical trial; willing to provide proof of identity;
  • Subjects or guardians must provide forms with personal signature and date;
  • Male and female of childbearing age should agree to take effective measures;
  • Subjects or guardians can obey the requirements of the clinical study;
  • Axillary temperature below 37.3 °C.

Exclusion criteria

Exclusion Criteria:

  • Laboratory indicators (expect those have no clinical significance) out of normal ranges required;
  • Received any pneumococcal vaccine;
  • Allergic history to any drugs, vaccine or vaccine-related component;
  • Infants with congenital malformations, developmental disorders, genetic defects, or severe malnutrition;
  • Infants diagnosed with pathological jaundice that lasts for 2\~4 weeks and occurs repeatedly;
  • Breast-feeding or pregnant women, or positive U-HCG;
  • High blood pressure uncontrolled by medication;
  • Known or suspected immune deficiency or immune suppression;
  • Serious congenital malformation, history of organ resection or serious chronic illness;
  • Received blood products or intravenous immunoglobulin (except immunoglobulin);
  • History of clinic-proven or serology-proven infectious disease especially caused by streptococcus pneumoniae;
  • History of convulsions, epilepsy or encephalopathy or a family history of mental illness;
  • A vaccination-related that other investigator believes;
  • Plans to participate in or is participating in any other clinical study;
  • Any other factors judged by investigator that may interfere subject's compliance with the protocol.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
264 participants (estimated)

Study arms

  • Experimental
    1A

    Subjects received one dose of PCV13 at 18 years of age and above.

    Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine

  • Experimental
    2A

    Subjects received one dose of PCV13 at 6\~17 years of age.

    Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine

  • Experimental
    3A

    Subjects received one dose of PCV13 at 2\~5 years of age.

    Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine

  • Experimental
    4A

    Subjects received two doses of PCV13 at 12\~23 months of age.

    Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine

  • Experimental
    5A

    Subjects received three doses of PCV13 at 7\~11 months of age.

    Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine

  • Experimental
    6A

    Subjects received four doses of PCV13 at 3 months of age.

    Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine

  • Experimental
    6B

    Subjects received four doses of PCV13 at 2 months of age (At least 6 weeks old).

    Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine

  • Active comparator
    6C

    Subjects received four doses of control PCV13 at 2 months of age (At least 6 weeks old).

    Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine

  • Experimental
    7A

    Subjects received four doses of PCV13 at 2 months of age (At least 6 weeks old).

    Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine

  • Active comparator
    7B

    Subjects received four doses of control PCV13 at 2 months of age (At least 6 weeks old).

    Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Safety in terms of adverse reactions

    Occurrence of AEs on vaccination site (local) and non-vaccination site (systemic) of each subject

    Time frame: within 30 minutes post each vaccination

  2. Safety in terms of adverse events

    Occurrence of solicited AEs of each subject

    Time frame: within 7 days post each vaccination

  3. Safety in terms of adverse events

    Occurrence of non-solicited AEs of each subject

    Time frame: within 30 days post each vaccination

  4. Safety in terms of SAEs

    Occurrence of SAEs of each subject

    Time frame: within 6 months post last vaccination

  5. Safety in terms of laboratory-based AEs

    Occurrence of laboratory-based AEs in subjects of 2 years old and above(Arm 1A-3A)

    Time frame: within 4 days post each vaccination

Secondary outcomes

  1. Immunogencity in terms of seropositivity rates by ELISA

    Seropositivity rates of serotype-specific pneumococcal IgG antibody in subjects of each age group

    Time frame: 30 days post basic vaccination

  2. Immunogencity in terms of GMC by ELISA

    GMC of serotype-specific pneumococcal IgG antibody in subjects of each age group

    Time frame: 30 days post basic vaccination

  3. Immunogencity in terms of subjects with IgG concentrations ≥1.0 µg/mL

    Percentage of subjects with serotype-specific IgG concentrations ≥1.0 µg/mL

    Time frame: 30 days post basic vaccination

  4. Immunogencity Comparison with control vaccine group

    Comparison of the seropositivity rates, GMC of serotype-specific pneumococcal IgG antibody and the Percentage of subjects with serotype-specific IgG concentrations ≥1.0 µg/mL in subjects aged 2 months of Experimental group and Control group

    Time frame: 30 days post basic vaccination

07

Study locations

1 of 1 sites recruiting
  • Xiangtan Maternal and Child Health Hospital
    Xiangtan, Hunan, China
    Recruiting
    • Tao Huang · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Jun 2024, 19 months after the start.

Of 27 phase 1 interventional studies under Pneumococcal Infections, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's planned 19 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2022
First posted
Nov 2, 2022
StartActual
Nov 1, 2022
Primary completionEst.
Jun 2024
CompletionEst.
Dec 2024
Last update
Nov 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05602480
Lead sponsor
Wuhan BravoVax Co., Ltd.
Collaborators
Hunan Provincial Center for Disease Control and Prevention, Liaoning Chengda Biotechnology CO., LTD
Responsible party
Sponsor
First posted
Nov 2, 2022
Start date
Nov 1, 2022
Primary completion
Jun 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Nov 17, 2022

Study contacts

Long Xu, Ph.D.
Contact
ct@bravovax.com
+86 27 8798 8585 ext. 8251

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion